ACD and Leica Biosystems co-market RNA in situ hybridisation platform

Leica Biosystems and Advanced Cell Diagnostics (ACD) are co-marketing ACD’s RNAscope LS ISH assays with Leica Biosystems’ Bond RX research staining platform. The agreement provides researchers with an integrated and fully automated ISH solution.

The RNAscope assays offer robust single RNA molecule detection for formalin-fixed, paraffin-embedded (FFPE) tissue. The assays have been used by pharma biotech companies and research institutions for drug discovery, translational research and the development of clinical and companion diagnostic tests. They are fully automated on the Bond RX platform - an open and flexible system which automates staining to provide a fast, high-throughput workflow with good consistency and minimal hands-on time.

“Automation is essential for pharma, biotech, translational labs and academic institutions to apply the RNA ISH technology to a wide range of biomarker analysis applications,” said Dr Yuling Luo, president and CEO of ACD. “We are very pleased to work with Leica Biosystems to expand our automated RNAscope solutions in response to the needs of our rapidly growing customer base.”

“Leica is excited to announce the availability of ACD’s RNAscope Assays fully automated on the Bond RX,” added Dr David Atkins, VP advanced staining at Leica Biosystems. “This is another example of how, with its openness and flexibility, the Bond RX is providing researchers with enhanced tools to help speed up important discoveries and improve cancer diagnostics.”

The RNAscope LS reagent kits and ISH probes are available from ACD, while the Bond RX instrument and associated reagents are supplied by Leica Biosystems.